$533 Million is the total value of 5AM Venture Management, LLC's 17 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 18.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | PEAR THERAPEUTICS INC | $115,517,000 | – | 18,631,771 | +100.0% | 21.68% | – | |
| New | ENTRADA THERAPEUTICS INC | $75,471,000 | – | 4,408,379 | +100.0% | 14.16% | – | |
| VOR | Sell | VOR BIOPHARMA INC | $73,923,000 | -29.6% | 6,361,723 | -4.9% | 13.88% | -34.9% |
| RALLYBIO CORP | $39,980,000 | -45.7% | 4,190,724 | 0.0% | 7.50% | -49.8% | ||
| AKUS | AKOUOS INC | $35,154,000 | -26.8% | 4,135,784 | 0.0% | 6.60% | -32.3% | |
| IDYA | IDEAYA BIOSCIENCES INC | $33,050,000 | -7.3% | 1,398,066 | 0.0% | 6.20% | -14.3% | |
| ARVN | ARVINAS INC | $32,856,000 | -0.0% | 400,000 | 0.0% | 6.17% | -7.6% | |
| IMPL | IMPEL NEUROPHARMA INC | $24,896,000 | -29.1% | 2,884,791 | 0.0% | 4.67% | -34.5% | |
| CRNX | Sell | CRINETICS PHARMACEUTICALS IN | $24,498,000 | -14.6% | 862,286 | -36.7% | 4.60% | -21.0% |
| SCPH | SCPHARMACEUTICALS INC | $19,234,000 | -24.5% | 3,831,474 | 0.0% | 3.61% | -30.2% | |
| FIXX | HOMOLOGY MEDICINES INC | $16,511,000 | -53.7% | 4,535,919 | 0.0% | 3.10% | -57.2% | |
| ISEE | Sell | IVERIC BIO INC | $10,755,000 | -14.0% | 643,248 | -16.5% | 2.02% | -20.5% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $9,283,000 | -32.2% | 390,555 | -29.7% | 1.74% | -37.3% |
| JANX | JANUX THERAPEUTICS INC | $8,805,000 | -8.8% | 446,266 | 0.0% | 1.65% | -15.7% | |
| CABA | Sell | CABALETTA BIO INC | $7,824,000 | -72.7% | 2,064,263 | -12.5% | 1.47% | -74.8% |
| FVAM | 5 01 ACQUISITION CORP | $3,596,000 | +0.3% | 365,126 | 0.0% | 0.68% | -7.3% | |
| CDTX | CIDARA THERAPEUTICS INC | $1,441,000 | -43.3% | 1,134,511 | 0.0% | 0.27% | -47.7% | |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -169,748 | -100.0% | -0.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HOMOLOGY MEDICINES INC | 16 | Q3 2023 | 26.6% |
| ARVINAS INC | 16 | Q3 2023 | 14.3% |
| Crinetics Pharmaceuticals, Inc. | 16 | Q3 2023 | 12.8% |
| SCPHARMACEUTICALS INC | 16 | Q3 2023 | 7.5% |
| CIDARA THERAPEUTICS INC | 16 | Q3 2023 | 1.7% |
| IDEAYA BIOSCIENCES INC | 14 | Q1 2023 | 11.4% |
| VOR BIOPHARMA INC | 11 | Q3 2023 | 51.9% |
| CABALETTA BIO INC | 11 | Q2 2022 | 14.2% |
| AKOUOS INC | 10 | Q3 2022 | 27.7% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.1% |
View 5AM Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-03 |
| 13F-HR | 2021-11-15 |
View 5AM Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.